Metabolite profiling of LADA challenges the view of a metabolically distinct subtype
Al-Majdoub, Mahmoud LU ; Ali, Arslan ; Storm, Petter LU
; Rosengren, Anders H.
LU
; Groop, Leif
LU
and Spégel, Peter
LU
(2017)
In Diabetes
66(4).
p.806-814
- Abstract
Latent autoimmune diabetes in adults (LADA) usually refers to GAD65 autoantibodies (GADAb)-positive diabetes with onset after 35 years of age and no insulin treatment within the first 6 months after diagnosis. However, it is not always easy to distinguish LADA fromtype 1 or type 2 diabetes. In this study, we examined whether metabolite profiling could help to distinguish LADA (n = 50) from type 1 diabetes (n = 50) and type 2 diabetes (n = 50). Of 123 identified metabolites, 99 differed between the diabetes types. However, no unique metabolite profile could be identified for any of the types. Instead, the metabolome varied along a C-peptide-driven continuum from type 1 diabetes via LADA to type 2 diabetes. LADA was more similar to type 2... (More)
Latent autoimmune diabetes in adults (LADA) usually refers to GAD65 autoantibodies (GADAb)-positive diabetes with onset after 35 years of age and no insulin treatment within the first 6 months after diagnosis. However, it is not always easy to distinguish LADA fromtype 1 or type 2 diabetes. In this study, we examined whether metabolite profiling could help to distinguish LADA (n = 50) from type 1 diabetes (n = 50) and type 2 diabetes (n = 50). Of 123 identified metabolites, 99 differed between the diabetes types. However, no unique metabolite profile could be identified for any of the types. Instead, the metabolome varied along a C-peptide-driven continuum from type 1 diabetes via LADA to type 2 diabetes. LADA was more similar to type 2 diabetes than to type 1 diabetes. In a principal component analysis, LADA patients overlapping with type 1 diabetes progressed faster to insulin therapy than those overlapping with type 2 diabetes. In conclusion, we could not find any unique metabolite profile distinguishing LADA from type 1 and type 2 diabetes. Rather, LADA was metabolically an intermediate of type 1 and type 2 diabetes, with those patients closer to the former showing a faster progression to insulin therapy than those closer to the latter.
(Less)
- author
- Al-Majdoub, Mahmoud
LU
; Ali, Arslan
; Storm, Petter
LU
; Rosengren, Anders H.
LU
; Groop, Leif
LU
and Spégel, Peter
LU
- organization
- publishing date
- 2017-04-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- ANDIS, diabetes, diabetics
- in
- Diabetes
- volume
- 66
- issue
- 4
- pages
- 9 pages
- publisher
- American Diabetes Association Inc.
- external identifiers
-
- pmid:27913577
- wos:000397114900005
- scopus:85019567445
- ISSN
- 0012-1797
- DOI
- 10.2337/db16-0779
- language
- English
- LU publication?
- yes
- id
- 8bff9d7f-8842-4c0a-b558-e28eb5f9351c
- date added to LUP
- 2017-07-03 17:54:23
- date last changed
- 2024-09-02 03:08:40
@article{8bff9d7f-8842-4c0a-b558-e28eb5f9351c,
abstract = {{<p>Latent autoimmune diabetes in adults (LADA) usually refers to GAD65 autoantibodies (GADAb)-positive diabetes with onset after 35 years of age and no insulin treatment within the first 6 months after diagnosis. However, it is not always easy to distinguish LADA fromtype 1 or type 2 diabetes. In this study, we examined whether metabolite profiling could help to distinguish LADA (n = 50) from type 1 diabetes (n = 50) and type 2 diabetes (n = 50). Of 123 identified metabolites, 99 differed between the diabetes types. However, no unique metabolite profile could be identified for any of the types. Instead, the metabolome varied along a C-peptide-driven continuum from type 1 diabetes via LADA to type 2 diabetes. LADA was more similar to type 2 diabetes than to type 1 diabetes. In a principal component analysis, LADA patients overlapping with type 1 diabetes progressed faster to insulin therapy than those overlapping with type 2 diabetes. In conclusion, we could not find any unique metabolite profile distinguishing LADA from type 1 and type 2 diabetes. Rather, LADA was metabolically an intermediate of type 1 and type 2 diabetes, with those patients closer to the former showing a faster progression to insulin therapy than those closer to the latter.</p>}},
author = {{Al-Majdoub, Mahmoud and Ali, Arslan and Storm, Petter and Rosengren, Anders H. and Groop, Leif and Spégel, Peter}},
issn = {{0012-1797}},
keywords = {{ANDIS; diabetes; diabetics}},
language = {{eng}},
month = {{04}},
number = {{4}},
pages = {{806--814}},
publisher = {{American Diabetes Association Inc.}},
series = {{Diabetes}},
title = {{Metabolite profiling of LADA challenges the view of a metabolically distinct subtype}},
url = {{http://dx.doi.org/10.2337/db16-0779}},
doi = {{10.2337/db16-0779}},
volume = {{66}},
year = {{2017}},
}